Pulmonary Valve Replacement for Tetralogy of Fallot

Area of Science:

• Cardiology
• Interventional Cardiology
• Congenital Heart Disease

Background:

• Right ventricular outflow tract (RVOT) dysfunction is a frequent complication after surgical repair of complex congenital heart disease, such as tetralogy of Fallot.
• This dysfunction can lead to pulmonary stenosis or regurgitation, potentially causing right ventricular failure and arrhythmias.
• Transcatheter valve technologies present a minimally invasive option for managing RVOT dysfunction.

Purpose of the Study:

• To review current indications for treating RVOT dysfunction.
• To discuss existing transcatheter valve technologies for RVOT dysfunction.
• To highlight investigational devices for RVOT dysfunction.

Main Methods:

• Review of current literature on transcatheter valve therapies for RVOT dysfunction.
• Discussion of approved devices (Medtronic Melody, Edwards SAPIEN XT) and their off-label use.
• Overview of investigational devices (Medtronic Harmony, Edwards Alterra Prestent) for patulous RVOT.

Main Results:

• Approved transcatheter valves demonstrate durable relief of pulmonary stenosis and regurgitation in RVOT conduits.
• Off-label use in nonconduit tracts is increasing, with associated procedural and long-term complications.
• Investigational devices aim to address RVOTs too large for current valves.

Conclusions:

• Transcatheter pulmonary valve implantation is a viable and evolving treatment for RVOT dysfunction.
• Ongoing technological advancements promise broader applicability in the future.
• Further research and clinical trials are crucial for expanding treatment options.